Insulin Market to exceed US$ 31.5 Bn by 2035, expanding at 4.1% CAGR, driven by rising diabetes prevalence and growing access to advanced therapies.

WILMINGTON, DE, UNITED STATES, August 22, 2025 /EINPresswire.com/ -- The global insulin market, valued at US$ 20.3 billion in 2024, is projected to grow steadily at a CAGR of 4.1% between 2025 and 2035, ultimately reaching US$ 31.5 billion by 2035. This growth is underpinned by the rising prevalence of diabetes, technological advances in insulin delivery systems, favorable government support, and an expansion in research and development (R&D) aimed at improving therapeutic efficiency and reducing side effects.

As the International Diabetes Federation (IDF) has emphasized, diabetes is rapidly becoming one of the most pressing health concerns worldwide. By 2025, 1 in 8 adults, or approximately 853 million people, are expected to be living with diabetes, of which around 90% will be cases of type 2 diabetes. This sharp rise in incidence is anticipated to fuel the consistent demand for insulin and associated delivery technologies across global markets.

The insulin industry is also witnessing a transformation through the convergence of nanotechnology, artificial intelligence (AI), and connected health platforms, enabling better disease management and improved patient compliance. In parallel, manufacturers are expanding into emerging economies with cost-effective insulin options to cater to underserved populations in low- and middle-income countries (LMICs).

For detailed insights and a Sample report, Request access today!

Analyst Viewpoint on Insulin Market Growth Drivers

Analysts highlight four key factors influencing the industry’s trajectory:

Increase in Diabetes Prevalence: Lifestyle-related factors such as obesity, sedentary habits, and urbanization are contributing to soaring diabetes rates globally. A significant portion of this burden is concentrated in low- and middle-income regions where access to insulin remains a critical challenge.

Technological Advancements: From intelligent insulin pens to automated insulin pumps integrated with continuous glucose monitoring (CGM), innovation is significantly improving glycemic management. Smart technologies reduce hypoglycemia risk, optimize dosing, and enhance user experience.

Favorable Government Policies and Investments: Strategic initiatives such as subsidies for essential diabetes medicines, public-private partnerships, and improved insurance coverage are making insulin more accessible to patients in key markets.

R&D and Emerging Therapies: Significant funding is being directed toward the development of next-generation insulin molecules, including oral insulin formulations and ultra-long-acting insulins. The development of nanotechnology-based insulin, such as the 2024 University of Sydney breakthrough in oral insulin, exemplifies the shift toward innovative, patient-friendly therapies.

Market Overview: Insulin as a Critical Therapy

Insulin is a hormone produced by the pancreas that regulates glucose metabolism and ensures energy balance in the human body. In therapeutic form, insulin is utilized to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and associated complications.

The most widely used preparation, U-100 insulin, is administered as an adjunct to diet and exercise to manage blood glucose levels effectively. The industry is broadly divided into human insulin and insulin analogs, with analogs gaining popularity due to their enhanced pharmacological properties, predictable absorption, and reduced risk of adverse effects.

Key Market Drivers

Rising Incidence of Diabetes

The IDF Diabetes Atlas underscores the growing diabetes epidemic, projecting a 46% increase in cases by 2035. Key drivers include:

Rising obesity rates
Genetic predispositions
Rapid urbanization and sedentary lifestyles
Increasing lifespan and aging populations
Alarmingly, nearly 240 million adults remain undiagnosed, emphasizing the urgent need for improved screening and affordable access to insulin therapies.

Advancements in Delivery Systems

Insulin delivery methods have undergone revolutionary improvements in recent years. The market has shifted from syringe-based systems to pens, pumps, patches, and jets, which enhance convenience, precision, and patient compliance.

Notable advancements include:

Smart Pens: Track insulin doses and integrate with smartphone applications for data sharing.
Automated Pumps: Devices like Omnipod 5 and Tandem’s Control IQ+, recently cleared by the FDA, automate insulin delivery by syncing with CGM systems.
Patch Pumps: Lightweight, portable pumps offering discrete, needle-free insulin delivery.
Oral Insulin Research: Nanotechnology-based oral formulations are in clinical trials, aiming to eliminate the need for injections altogether.
The American Diabetes Association’s Standards of Care 2025 reinforces the importance of CGM for all insulin users, signaling broader adoption of connected health devices that integrate with insulin therapies.

Product Type Analysis

Long-acting Insulin: The Leading Segment

Long-acting insulins dominate the global market by product type. These formulations mimic basal insulin release in the body, ensuring stable glucose control with fewer daily injections. Key products include:

Insulin glargine
Insulin detemir
Insulin degludec

Advantages such as reduced hypoglycemia risk, improved patient adherence, and once-daily dosing make long-acting insulin highly preferable for both type 1 and advanced type 2 diabetes patients. Analysts forecast this segment will continue to capture the largest market share through 2035.

Other Product Segments

Rapid-acting Insulin: Crucial for mealtime glucose control.
Short-acting Insulin: Traditional insulin therapy, still widely used in some regions.
Intermediate-acting Insulin: Offers a middle-ground solution between short- and long-acting types.
Biphasic Insulin: A premixed solution combining short- and intermediate-acting insulin, offering convenience for patients with complex regimens.

Application Insights

Type 1 Diabetes: Insulin therapy is essential and lifelong, driving consistent demand.
Type 2 Diabetes: Rising prevalence, especially in developing countries, is driving significant adoption of long-acting and premixed insulins.
Gestational Diabetes: Increasing maternal health screening is fueling steady growth in this niche application.

Delivery Devices in Focus

Insulin Pens – User-friendly, portable, and the most popular method globally.
Insulin Pumps – Automated, precise, and increasingly integrated with CGMs.
Syringes – Still widely used in low-income markets due to cost advantages.
Jet Injectors – Emerging, needle-free delivery technology with growing appeal.

Regional Outlook

North America: The Dominant Market

North America leads the global insulin market, driven by:

High diabetes prevalence rates
Strong adoption of advanced delivery systems
Robust healthcare infrastructure
Presence of key pharmaceutical giants such as Eli Lilly and Novo Nordisk
The United States is the largest contributor, supported by favorable reimbursement policies, high patient awareness, and cutting-edge research collaborations.

Europe

Europe shows consistent demand for both human insulin and analogs, with governments enforcing strong healthcare policies. Western European nations, including Germany, France, and the U.K., are at the forefront of adoption.

Asia Pacific

Asia Pacific is the fastest-growing region due to:

High population density
Rising diabetes prevalence in India and China
Expanding healthcare infrastructure
Local production capabilities driving cost reductions
Middle East & Africa (MEA)

MEA markets such as Saudi Arabia, UAE, and South Africa are expanding rapidly, driven by government healthcare investments and increasing awareness campaigns.

Latin America

Countries like Brazil and Mexico represent promising markets due to rising obesity rates and increasing middle-class populations.

Competitive Landscape

The insulin market is moderately consolidated, with global pharmaceutical companies holding significant market shares. Leading players include:

Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Biocon Ltd.
Tonghua Dongbao
Shanghai Fosun Pharmaceutical Co., Ltd.
Julphar
Ypsomed AG
Becton, Dickinson, and Company
B. Braun Melsungen AG

Key Developments

December 2024: EVA Pharma and Eli Lilly collaboration secured approval for insulin glargine injection in Egypt, aiming to deliver affordable insulin across LMICs.

June 2024: Teva Pharmaceuticals launched an authorized generic of Victoza1 in the U.S., increasing competitive pricing pressure in the GLP-1 receptor agonist segment.

These developments highlight the dual market strategy of innovation in high-income countries and affordability-focused expansions in LMICs.

Market Snapshot

Size in 2024: US$ 20.3 Bn
Forecast Value in 2035: US$ 31.5 Bn
CAGR (2025–2035): 4.1%
Segmentation: By product type, application, delivery device, source, and distribution channel
Leading Region: North America
Fastest-growing Region: Asia Pacific

The global insulin market is set for steady growth, shaped by the dual dynamics of increasing disease prevalence and technological innovation. Long-acting insulins will continue to dominate product adoption, while smart devices and oral formulations are poised to transform patient experiences.

The industry’s trajectory also highlights a crucial equity challenge: ensuring that the millions of undiagnosed and untreated patients in low- and middle-income countries have consistent, affordable access to insulin therapies. Companies that balance innovation with affordability are expected to remain leaders in this evolving and highly competitive market.

By 2035, the insulin industry will not only be larger in value but also smarter, more connected, and more inclusive, paving the way for a future where diabetes care is more effective and patient-centered than ever before.

Access More Trending Exclusive Reports by Transparency Market Research:

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Atil Chaudhari
Transparency Market Research Inc.
+1 518-618-1030
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media